Photon-counting CT and ultrasound for detecting liver fat and scarring

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional imaging study compares photon-counting CT (PCCT) and ultrasound against MRI to determine how well each modality detects hepatic steatosis and fibrosis. Eligible adults scheduled for a clinically indicated liver CT will receive a PCCT scan with a few additional research images, an MRI (same day or another day by preference), and an ultrasound on the day of the MRI. A hematocrit blood test will be taken if not performed within 24 hours prior to CT. Imaging results from PCCT and ultrasound will be compared to MRI as the reference standard.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age of 18 years or older
* Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)
* Patient eligible for MR imaging
* History of chronic diffuse liver disease, steatotic liver disease, and/ or liver fibrosis
* Capable of consent

Exclusion Criteria:

* Contraindications to any of the required imaging examinations
* BMI \> 45 (based on MRI scanner capacity)

Where it's running

• Duke University Medical Center
  Durham, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Mustafa Bashir, MD — Duke University
• Study coordinator: Mustafa Bashir, MD
• Email: mustafa.bashir@duke.edu
• Phone: 919-684-7366

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Pre-hepatectomy rehabilitation with mazdutide for obese MASLD donors

  This trial tests whether adding mazdutide to a structured lifestyle plan helps overweight MASLD donors lose liver fat faster to become eligible for donation.

  Recruiting Phase 4 West China Hospital · Hefei, Anhui and 3 other locations · NCT07718126

• Peanut intake and liver health in adults with MASLD

  This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.

  Recruiting Henry Ford Health System · Detroit, Michigan · NCT07646197

• Tesamorelin to reduce liver fat in adults with fatty liver disease

  This trial tests whether a daily self‑injection of tesamorelin can lower liver fat over 52 weeks in adults with fatty liver disease.

  Recruiting Phase 2 Hudson Biotech · Shenzhen, Guangdong · NCT07481734

• Erdosteine for nonalcoholic fatty liver disease

  This trial will try erdosteine alongside standard therapy in adults with nonalcoholic fatty liver disease confirmed by ultrasound to see if it improves liver fat and liver health.

  Recruiting Phase 1/2 Tanta University · Tanta · NCT07242222

• Cilostazol for nonalcoholic fatty liver disease.

  This trial will test whether the medicine cilostazol can reduce liver fat and improve liver health in adults with nonalcoholic fatty liver disease.

  Recruiting Phase 1/2 Tanta University · Damietta, New Damietta · NCT07238985

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.